The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer.

[1]  H. Wada,et al.  D2-40-Positive Lymphatic Vessel Density Is a Poor Prognostic Factor in Squamous Cell Carcinoma of the Lung , 2009, Annals of Surgical Oncology.

[2]  D. Cassarino,et al.  Immunohistochemical Expression of D2-40 in Benign and Malignant Sebaceous Tumors and Comparison to Basal and Squamous Cell Carcinomas , 2008, The American Journal of dermatopathology.

[3]  H. Okabe,et al.  Immunohistochemical demonstration of D2‐40 in basal cell carcinomas of the skin , 2008, Journal of cutaneous pathology.

[4]  R. Haba,et al.  The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. , 2008, European journal of cancer.

[5]  K. Iczkowski,et al.  Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. , 2008, Human pathology.

[6]  A. Longatto-Filho,et al.  Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix. , 2007, Gynecologic oncology.

[7]  C. Chai,et al.  Expression of D2‐40 in adjunct diagnosis of papillary thyroid carcinoma , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  M. Okada,et al.  Novel marker D2‐40, combined with calretinin, CEA, and TTF‐1 , 2007, Cancer.

[9]  H. Moch,et al.  D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation , 2007, Modern Pathology.

[10]  S. Narod,et al.  Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer , 2007, Modern Pathology.

[11]  T. Kameya,et al.  Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody, D2-40. , 2006, Human pathology.

[12]  M. Fukushima,et al.  Tailor-made chemotherapy for non-small cell lung cancer patients. , 2006, Future oncology.

[13]  J. Tímár,et al.  Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[14]  R. Haba,et al.  Clinical application of biological markers for treatments of resectable non-small-cell lung cancers , 2005, British Journal of Cancer.

[15]  H. Dvorak,et al.  T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema , 2003, The EMBO journal.

[16]  Alexander Marks,et al.  A New Monoclonal Antibody, D2-40, for Detection of Lymphatic Invasion in Primary Tumors , 2002, Laboratory Investigation.

[17]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[18]  R. J. Cersosimo.  Lung cancer: a review. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  Akira Yamauchi,et al.  The intratumoral expression of vascular endothelial growth factor and interleukin‐8 associated with angiogenesis in nonsmall cell lung carcinoma patients , 2001, Cancer.

[20]  H. Yeger,et al.  Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours , 1999, British Journal of Cancer.

[21]  R. Muraoka,et al.  Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. , 1998, The Annals of thoracic surgery.

[22]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[23]  三村 剛史.  Novel marker D2-40, combined with calretinin, CEA, and TTF-1 : an optimal set of immunodiagnostic markers for pleural mesothelioma , 2007 .

[24]  Xiaowei Xu,et al.  Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix , 2005, Modern Pathology.

[25]  M. Detmar,et al.  Up-regulation of the lymphatic marker podoplanin in human squamous cell carcinomas and germ cell tumors , 2004 .